PET Scan after Chemo Could Avoid Need for Radiotherapy
The "RAPID" trial involved 602 Hodgkin lymphoma patients who had a PET scan performed after their chemotherapy. Patients who tested positive received radiotherapy. Those who tested negative were split into two groups – one group of 211 patients received no further treatment, while the other group of 209 had the standard radiotherapy.
After three years of regular check-ups, researchers found that the proportion of patients who were alive and free of disease was 94.6 percent in the radiotherapy group, and 90.8 percent in the group that did not receive further treatment.
"The results of RAPID show that in early stage Hodgkin lymphoma radiotherapy after initial chemotherapy marginally reduces the recurrence rate, but this is bought at the expense of exposing to radiation all patients with negative PET findings, most of whom are already cured,” said lead researcher Professor John Radford, who is based at The University of Manchester’s Institute of Cancer Sciences and the Christie NHS Foundation Trust.
The research team notes that a longer follow-up period is needed in order to determine whether this approach will ultimately lead to fewer late side-effects and improved overall survival.
Hodgkin lymphoma is a cancer that develops in the lymphatic system, which is a network of vessels and glands spread throughout the body. The current standard treatment is for patients to receive chemotherapy, followed by radiotherapy. However, this radiotherapy comes with undesirable late effects, such as cardiovascular disease and other cancers – despite the fact that they have already been cured of Hodgkin lymphoma.
In the UK, some 1,900 people, many of whom are teenagers and young adults, are diagnosed with the disease every year.
The RAPID study was funded by Leukaemia & Lymphoma Research. Dr. Matt Kaiser, Head of Research at the charity, said: “This groundbreaking clinical trial shows that, by using scans to predict an individual's risk of relapse, many patients can remain disease-free with just chemotherapy alone. Radiotherapy can cause a range of long-term problems like heart disease and hard-to-treat second cancers. As many Hodgkin lymphoma patients are relatively young, it is particularly important to avoid using intensive treatment when it is unnecessary.”
Source: University of Manchester
Image Credit: King's College London
Published on : Thu, 23 Apr 2015
Based on Mindray's new generation ultrasound platform, mQuadro, M9 has raised the industry standards to an all new level. Advanced signal transmission and reception processors provide highly sensitive and accurate echo detection. Innovative transducer...
We recognize that the best chance any patient has at getting better is a clinician at their bedside with all the right answers and the confidence to act. SonoSite education and training is the industry standard – no other point-of-care ultrasound manufacturer...
GM85 from Samsung is a mobile digital radiography system which allows easy navigation through anywhere with its compact design. Long lasting battery and superior user experience with SID Guide and S-Align deliver optimized workflow with enhanced usability....
Shown to improve comfort in 93% of patients who reported moderate to severe discomfort with standard compression technology2 Curved, unique design mirrors the shape of a woman’s breast to reduce pinching and apply uniform compression over the entire...
Samsung’s advanced premium ultrasound system for Radiology that provides enhanced image quality, and convenience for medical and radiology professionals. The RS85 features MV-Flow technology, which detects blood flow in microvascular, and S-Shearwave...